Wc. Levy et al., Early patency of she infarct-related artery after myocardial infarction preserves diastolic filling, AM J CARD, 87(8), 2001, pp. 955-958
Citations number
30
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
A patent infarct-related artery (IRA) following myocardial infarction has b
een associated with lower mortality, increased systolic function, decreased
left ventricular remodeling, and electrical stability. The purpose of this
study was to determine whether coronary artery patency early after myocard
ial infarction is associated with greater early diastolic filling than a cl
osed artery. Radionuclide ventriculograms were performed at a central labor
atory on 167 patients who received alteplase for an acute myocardial infarc
tion and had infarct artery potency determined by cardiac catheterization.
The peak early filling rate (PEFR) was assessed by 4 different methods: (1)
PEFR (EDV/s)-normalized to the end-diastolic volume; (2) PEFR (SV/s)-norma
lized to the stroke volume; (3) PEFR (ml/s/m(2))-an absolute diastolic fill
ing rate; and (4) PEFR (PER)-normalized to the peak ejection rate. Patients
with a closed IRA (n = 16, Thrombolysis In Myocardial Infarction [TIMI] 0
or 1 few) and patients with an open IRA (n = 151, TIMI 2 or 3 flow) had sim
ilar ages, ejection fractions, and cardiac volumes. However, among patients
with an occluded IRA, the PEFR was decreased by 12% to 18% by the 4 measur
es of diastolic filling (3 of 4 methods, p <0.05). PEFR (EDV/s) was 1.69 <p
lus/minus> 0.9 in the occluded group versus 2.06 +/- 0.4 EDV/s in the open
artery group (p = 0.005). By multivariate analysis, IRA potency was an inde
pendent predictor of the PEFR by all 4 methods. Early coronary artery poten
cy after an acute myocardial infarction preserves diastolic filling. Improv
ed diastolic function may in past explain part of the long-term benefits of
a patent IRA after thrombolytic therapy when there is no documented improv
ement in the ejection fraction. (C) 2001 by Excerpta Medico, Inc.